Inavolisib (GDC‐0077) is a PI3Kα‐selective inhibitor that has shown promising antitumor activity in patients with PIK3CA‐mutated HR+/HER2− locally advanced BC (LABC) or MBC [339]. Here, ERBB2 is linked to breast cancer.